EU recommends licensing drug to prevent COVID-19 Evosheld

Recommendations will be sent to the European Commission (EC) for this competent authority to authorize the circulation of products on the market of 27 member countries of the European Union (EU).

According to the European Medicines Agency, drug Eveld of AstraZeneca injectable has a composition of two monoclonal antibodies tixagevimab and cilgavimab. These are two proteins used to attack the mutant proteins of the SARS-CoV-2 virus that causes COVID-19.

The drug can be used to prevent infection in patients with immune system problems or who have had a severe reaction to COVID-19 vaccines. Specifically, the drug has the ability to prevent the risk of infection with SARS-CoV-2 virus in adults and children from 12 years old.

The agency cited the results of a trial of more than 5,000 people who received two injections of Evusheld, which showed that the drug was up to 77% effective in reducing the risk of infection with the virus, had few side effects and was effective at protecting at least 6 month.

AstraZeneca’s Evusheld medicine for injection contains two monoclonal antibodies tixagevimab and cilgavimab. (Photo: AP)

The study was conducted in adults who had never had COVID-19 and had not received any COVID-19 vaccine or access to any treatment.

EMA confirms that the drug Evusheld is safe to use with relatively mild side effects when only a few people inject the drug with sensitization at the injection site. However, the EMA said, this experimental study was conducted at a time before the Omicron variant broke out.

At the end of 2021, the US Food and Drug Administration (FDA) has granted a marketing authorization for Evusheld and recently, the Ministry of Health of Vietnam has also granted a license to import this drug for use in medical facilities. sick.

* Invite readers to watch programs broadcast by Vietnam Television on TV Online and VTVGo!